The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease

Journal of Medicinal Food

Volumn 16, Issue 10, 2013, Pages 957-960

  Nobili, Valerio ^a   Bedogni, Giorgio ^b   Donati, Benedetta ^c   Alisi, Anna ^a   Valenti, Luca ^c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b Liver Research Center   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

children; docosahexaenoic acid; non Alcoholic fatty liver disease; randomized controlled trial

Indexed keywords

DOCOSAHEXAENOIC ACID; PHOSPHOLIPASE; PLACEBO;

ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG RESPONSE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PNPLA3 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SECONDARY ANALYSIS;

CHILD; CHILD, PRESCHOOL; DOCOSAHEXAENOIC ACIDS; FATTY LIVER; FEMALE; HUMANS; LIPASE; MALE; MEMBRANE PROTEINS; MUTATION, MISSENSE; TREATMENT OUTCOME;

EID: 84885970553     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.0043     Document Type: Article

References (26)

1. Nobili V, Svegliati-Baroni G, Alisi A, et al.: A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2012;58:1218-1229.
2. Bugianesi E, Leone N, Vanni E, et al.: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123: 134-140.
3. Nobili V, Bedogni G, Alisi A, et al.: Docosahexaenoic acid supplementation decreases liver fat content in children with non-Alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011;96:350-353.
4. Nobili V, Alisi A, Della Corte C, et al.: Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2012 [Epub ahead of print]; DOI: 10.1016/j.numecd.2012.10.010.
5. Valenti L, Alisi A, Galmozzi E, et al.: I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010;52:1274-1280.
6. Schwimmer JB, Celedon MA, Lavine JE, et al.: Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136: 1585-1592.
7. Romeo S, Kozlitina J, Xing C, et al.: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
8. Sookoian S, Pirola CJ: Meta-Analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-1894.
9. Valenti L, Al-Serri A, Daly AK, et al.: Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217.
10. Kumari M, Schoiswohl G, Chitraju C, et al.: Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012;15:691-702.
11. He S, McPhaul C, Li JZ, et al.: A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010;285:6706-6715.
12. Goran MI, Walker R, Le KA, et al.: Effects of PNPLA3 on liver fat and metabolic profile in Hispanic children and adolescents. Diabetes 2010;59:3127-3130.
13. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH: A common variant in the PNPLA3 gene is a risk factor for nonalcoholic fatty liver disease in obese Taiwanese children. J Pediatr 2011;158:740-744.
14. Romeo S, Sentinelli F, Cambuli VM, et al.: The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010;53:335-338.
15. Santoro N, Kursawe R, DAdamo E, et al.: A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010;52:1281-1290.
16. Davis JN, Le KA, Walker RW, et al.: Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010;92:1522-1527.
17. Miraglia del Giudice E, Grandone A, Cirillo G, et al.: The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS ONE 2011;6:e27933.
18. Santoro N, Savoye M, Kim G, et al.: Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS ONE 2012;7:e37827.
19. Newson R: Parameters behind nonparametric statistics: Kendalls tau, Somers D and median differences. Stat J 2002;2:45-64.
20. Newson R. SOMERSD: Stata Module to Calculate Kendalls Tau-A, Somers D and Median Differences. http://ideas.repec.org/c/boc/bocode/s336401.html (accessed January 2013).
21. Valenti L: PNPLA3 Ile148Met variant and hepatocellular carcinoma: a matter of fat. Dig Liver Dis 2012;44:974-975.
22. Li JZ, Huang Y, Karaman R, et al.: Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest 2012;122:4130-4144.
23. Huang Y, He S, Li JZ, et al.: A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA 2010;107:7892-7897.
24. Pirazzi C, Adiels M, Burza MA, et al.: Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012; 57:1276-1282.
25. Palmer CN, Maglio C, Pirazzi C, et al.: Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS ONE 2012;7:e39362.
26. Krarup NT, Grarup N, Banasik K, et al.: The PNPLA3 rs738409 G-Allele associates with reduced fasting serum triglyceride and serum cholesterol in Danes with impaired glucose regulation. PLoS ONE 2012;7:e40376.